Intratendinous adipose-derived stromal vascular fraction (SVF) injection provides a safe, efficacious treatment for Achilles tendinopathy: results of a randomized controlled clinical trial at a 6-month follow-up

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

44 patients with Achilles tendinopathy were randomized to an ultrasound-guided injection of either an adipose-derived stromal vascular fraction or leukocyte-rich platelet-rich plasma. Outcome measures included a visual analog scale for pain, the Victorian Institute of Sport Assessment-Achilles (VISA-A) questionnaire, the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score, and MRI-measured tendon lesion size. Follow-up was performed at 15 days, 30 days, 60 days, 120 days, and 180 days. Both treatments allowed for a significant improvement with respect to baseline, with stable results up to the last follow-up. Results demonstrated significantly better scores in the SVF group at 15 days for VAS pain and AOFAS ankle-hindfoot scores, and at 30 days for the VISA-A; at all other time points, groups did not significantly differ. No significant within-group reduction in lesion size on MRI was observed in either group.